[go: up one dir, main page]
Jump to content

Antigen presentation

From Wikipedia, the free encyclopedia
Antigen presentation stimulates T cells to become either "cytotoxic" CD8+ cells or "helper" CD4+ cells.

Antigen presentation is a vital immune process that is essential for T cell immune response triggering. Because T cells recognize only fragmented antigens displayed on cell surfaces, antigen processing must occur before the antigen fragment can be recognized by a T-cell receptor. Specifically, the fragment, bound to the major histocompatibility complex (MHC), is transported to the surface of the antigen-presenting cell, a process known as presentation. If there has been an infection with viruses or bacteria, the antigen-presenting cell will present an endogenous or exogenous peptide fragment derived from the antigen by MHC molecules. There are two types of MHC molecules which differ in the behaviour of the antigens: MHC class I molecules (MHC-I) bind peptides from the cell cytosol, while peptides generated in the endocytic vesicles after internalisation are bound to MHC class II (MHC-II).[1] Cellular membranes separate these two cellular environments - intracellular and extracellular. Each T cell can only recognize tens to hundreds of copies of a unique sequence of a single peptide among thousands of other peptides presented on the same cell, because an MHC molecule in one cell can bind to quite a large range of peptides.[2][3] Predicting which (fragments of) antigens will be presented to the immune system by a certain MHC/HLA type is difficult, but the technology involved is improving.[4]

Presentation of intracellular antigens: Class I

[edit]
Antigen processing and presentation in MHC-I pathway

Cytotoxic T cells (also known as Tc, killer T cell, or cytotoxic T-lymphocyte (CTL)) express CD8 co-receptors and are a population of T cells that are specialized for inducing programmed cell death of other cells. Cytotoxic T cells regularly patrol all body cells to maintain the organismal homeostasis. Whenever they encounter signs of disease, caused for example by the presence of viruses or intracellular bacteria or a transformed tumor cell, they initiate processes to destroy the potentially harmful cell.[1] All nucleated cells in the body (along with platelets) display class I major histocompatibility complex (MHC-I molecules). Antigens generated endogenously within these cells are bound to MHC-I molecules and presented on the cell surface. This antigen presentation pathway enables the immune system to detect transformed or infected cells displaying peptides from modified-self (mutated) or foreign proteins.[5][6]

In the presentation process, these proteins are mainly degraded into small peptides by cytosolic proteases in the proteasome, but there are also other cytoplasmic proteolytic pathways. Then, peptides are distributed to the endoplasmic reticulum (ER) via the action of heat shock proteins and the transporter associated with antigen processing (TAP) which translocates the cytosolic peptides into the ER lumen in an ATP-dependent transport mechanism. There are several ER chaperones involved in MHC-I assembly, such as calnexin, calreticulin, Erp57, protein disulfide isomerase (PDI),[7] and tapasin. Specifically, the complex of TAP, tapasin, MHS Class 1, ERp57, and calreticulin is called the peptide-loading complex (PLC).[8] Peptides are loaded to MHC-I peptide binding groove between two alpha helices at the bottom of the α1 and α2 domains of the MHC class I molecule. After releasing from tapasin, peptide-MHC-I complexes (pMHC-I) exit the ER and are transported to the cell surface by exocytic vesicles.[9][10]

Naïve anti-viral T cells (CD8+) cannot directly eliminate transformed or infected cells. They have to be activated by the pMHC-I complexes of antigen-presenting cells (APCs). Here, antigen can be presented directly (as described above) or indirectly (cross-presentation) from virus-infected and non-infected cells.[11] After the interaction between pMHC-I and TCR, in presence of co-stimulatory signals and/or cytokines, T cells are activated, migrate to the peripheral tissues and kill the target cells (infected or damaged cells) by inducing cytotoxicity.[citation needed]

Cross-presentation is a special case in which MHC-I molecules are able to present extracellular antigens, usually displayed only by MHC-II molecules. This ability appears in several APCs, mainly plasmacytoid dendritic cells in tissues that stimulate CD8+ T cells directly. This process is essential when APCs are not directly infected, triggering local antiviral and anti-tumor immune responses immediately without trafficking the APCs in the local lymph nodes.[6]

Presentation of extracellular antigens: Class II

[edit]
MHC II antigen processing pathway A Foreign protein; B Endosome; C Lysosome; D Late endosome/Endolysosome; E ER; F Golgi apparatus; G CLIP for antigen exchange; H Antigen presentation at plasma membrane

Antigens from the extracellular space and sometimes also endogenous ones,[12] are enclosed into endocytic vesicles and presented on the cell surface by MHC-II molecules to the helper T cells expressing CD4 molecule. Only APCs such as dendritic cells, B cells or macrophages express MHC-II molecules on their surface in substantial quantity, so expression of MHC-II molecules is more cell-specific than MHC-I.[citation needed]

APCs usually internalise exogenous antigens by endocytosis, but also by pinocytosis, macroautophagy, endosomal microautophagy or chaperone-mediated autophagy.[12] In the first case, after internalisation, the antigens are enclosed in vesicles called endosomes. There are three compartments involved in this antigen presentation pathway: early endosomes, late endosomes or endolysosomes and lysosomes, where antigens are hydrolized by lysosome-associated enzymes (acid-dependent hydrolases, glycosidases, proteases, lipases). This process is favored by gradual reduction of the pH. The main proteases in endosomes are cathepsins and the result is the degradation of the antigens into oligopeptides.[citation needed]

MHC-II molecules are transported from the ER to the MHC class II loading compartment together with the protein invariant chain (Ii, CD74). A non classical MHC-II molecule (HLA-DO and HLA-DM) catalyses the exchange of part of the CD74 (CLIP peptide) with the peptide antigen. Peptide-MHC-II complexes (pMHC-II) are transported to the plasma membrane and the processed antigen is presented to the helper T cells in the lymph nodes.[9]

APCs undergo a process of maturation while migrating, via chemotactic signals, to lymphoid tissues, in which they lose the phagocytic capacity and develop an increased ability to communicate with T-cells by antigen-presentation.[13] As well as in CD8+ cytotoxic T cells, APCs need pMHC-II and additional costimulatory signals to fully activate naive T helper cells.

Alternative pathway of endogenous antigen processing and presentation over MHC-II molecules exists in medullary thymic epithelial cells (mTEC) via the process of autophagy. It is important for the process of central tolerance of T cells in particular the negative selection of autoreactive clones. Random gene expression of the whole genome is achieved via the action of AIRE and a self-digestion of the expressed molecules presented on both MHC-I and MHC-II molecules.[citation needed]

Presentation of native intact antigens to B cells

[edit]

B-cell receptors on the surface of B cells bind to intact native and undigested antigens of a structural nature, rather than to a linear sequence of a peptide which has been digested into small fragments and presented by MHC molecules. Large complexes of intact antigen are presented in lymph nodes to B cells by follicular dendritic cells in the form of immune complexes. Some APCs expressing comparatively lower levels of lysosomal enzymes are thus less likely to digest the antigen they have captured before presenting it to B cells.[14][15]

See also

[edit]

References

[edit]
  1. ^ a b Janeway Jr CA, Travers P, Walport M, Shlomchik MJ (2001-01-01). "Chapter 5 Antigen Presentation to T Lymphocytes". Immunobiology: The Immune System in Health and Disease. 5th edition. Garland Science.
  2. ^ Purcell AW, Croft NP, Tscharke DC (June 2016). "Immunology by numbers: quantitation of antigen presentation completes the quantitative milieu of systems immunology!". Current Opinion in Immunology. 40: 88–95. doi:10.1016/j.coi.2016.03.007. PMID 27060633.
  3. ^ Janeway Jr CA, Travers P, Walport M, Shlomchik MJ (2001-01-01). "The major histocompatibility complex and its functions". Immunobiology: The Immune System in Health and Disease (5th ed.). Garland Science.
  4. ^ Bouzid R, de Beijer MT, Luijten RJ, Bezstarosti K, Kessler AL, Bruno MJ, Peppelenbosch MP, Demmers JA, Buschow SI (May 2021). "Empirical Evaluation of the Use of Computational HLA Binding as an Early Filter to the Mass Spectrometry-Based Epitope Discovery Workflow". Cancers. 13 (10): 2307. doi:10.3390/cancers13102307. PMC 8150281. PMID 34065814.
  5. ^ Hewitt EW (October 2003). "The MHC class I antigen presentation pathway: strategies for viral immune evasion". Immunology. 110 (2): 163–9. doi:10.1046/j.1365-2567.2003.01738.x. PMC 1783040. PMID 14511229.
  6. ^ a b Joffre OP, Segura E, Savina A, Amigorena S (July 2012). "Cross-presentation by dendritic cells". Nature Reviews. Immunology. 12 (8): 557–69. doi:10.1038/nri3254. PMID 22790179. S2CID 460907.
  7. ^ "Antigen Processing and Presentation | British Society for Immunology". www.immunology.org. Archived from the original on 2021-11-27. Retrieved 2021-11-27.
  8. ^ Thomas, Christoph; Tampé, Robert (2017). "Proofreading of Peptide—MHC Complexes through Dynamic Multivalent Interactions". Frontiers in Immunology. 8: 65. doi:10.3389/fimmu.2017.00065. ISSN 1664-3224. PMC 5296336. PMID 28228754.
  9. ^ a b Sinha JK, Bhattacharya S. A Text Book of Immunology. Academic Publishers. ISBN 9788189781095.
  10. ^ Nesmiyanov, Pavel P. (2020), "Antigen Presentation and Major Histocompatibility Complex", Reference Module in Biomedical Sciences, Elsevier, pp. 90–98, doi:10.1016/b978-0-12-818731-9.00029-x, ISBN 978-0-12-801238-3, S2CID 234948691, retrieved 2021-12-02
  11. ^ Sei JJ, Haskett S, Kaminsky LW, Lin E, Truckenmiller ME, Bellone CJ, et al. (June 2015). "Peptide-MHC-I from Endogenous Antigen Outnumber Those from Exogenous Antigen, Irrespective of APC Phenotype or Activation". PLOS Pathogens. 11 (6): e1004941. doi:10.1371/journal.ppat.1004941. PMC 4479883. PMID 26107264.
  12. ^ a b Stern LJ, Santambrogio L (June 2016). "The melting pot of the MHC II peptidome". Current Opinion in Immunology. 40: 70–7. doi:10.1016/j.coi.2016.03.004. PMC 4884503. PMID 27018930.
  13. ^ Flores-Romo L (March 2001). "In vivo maturation and migration of dendritic cells". Immunology. 102 (3): 255–62. doi:10.1046/j.1365-2567.2001.01204.x. PMC 1783189. PMID 11298823.
  14. ^ Batista FD, Harwood NE (January 2009). "The who, how and where of antigen presentation to B cells". Nature Reviews. Immunology. 9 (1): 15–27. doi:10.1038/nri2454. PMID 19079135. S2CID 2413048.
  15. ^ Harwood NE, Batista FD (December 2010). "Antigen presentation to B cells". F1000 Biology Reports. 2: 87. doi:10.3410/B2-87. PMC 3026618. PMID 21283653.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Antigen_presentation&oldid=1250791723"